Gestione delle reazioni avverse immuno-correlate durante la terapia con inibitori dei checkpoint immunologici

Translated title of the contribution: Management of immune-related adverse events during treatment with immune checkpoint inhibitors

Paola Queirolo, Francesco Spagnolo

Research output: Contribution to journalReview articlepeer-review

Abstract

Immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies is a breakthrough in the treatment of advanced cancer. The progressively broader indications of such drugs highlights the need of developing algorithms for the management of immune-related toxicities, as some adverse events may cause sequelae and even death if not managed effectively. Thanks to the collaboration of different specialist from the Gustave Roussy Institute in Paris, guidelines for the management of toxicities during treatment with immune checkpoint inhibitors were recently published on the journal Annals of Oncology. The purpose of this article is to review and discuss such guidelines.

Translated title of the contributionManagement of immune-related adverse events during treatment with immune checkpoint inhibitors
Original languageItalian
Pages (from-to)407-413
Number of pages7
JournalRecenti Progressi in Medicina
Volume107
Issue number8
DOIs
Publication statusPublished - Aug 1 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Management of immune-related adverse events during treatment with immune checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this